Latest news with #STAARSurgical
Yahoo
11-07-2025
- Business
- Yahoo
Masimo, STAAR Surgical, Teleflex, Omnicell, and Integra LifeSciences Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Patient Monitoring company Masimo (NASDAQ:MASI) fell 3.1%. Is now the time to buy Masimo? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company STAAR Surgical (NASDAQ:STAA) fell 3.4%. Is now the time to buy STAAR Surgical? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Teleflex (NYSE:TFX) fell 3%. Is now the time to buy Teleflex? Access our full analysis report here, it's free. Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) fell 3.7%. Is now the time to buy Omnicell? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Integra LifeSciences (NASDAQ:IART) fell 4.6%. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it's free. Integra LifeSciences's shares are very volatile and have had 26 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Integra LifeSciences is down 45.1% since the beginning of the year, and at $12.63 per share, it is trading 60.2% below its 52-week high of $31.74 from July 2024. Investors who bought $1,000 worth of Integra LifeSciences's shares 5 years ago would now be looking at an investment worth $272.55. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
3 Low-Volatility Stocks with Open Questions
A stock with low volatility can be reassuring, but it doesn't always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. Finding the right balance between safety and returns isn't easy, which is why StockStory is here to help. That said, here are three low-volatility stocks to steer clear of and a few better alternatives. Rolling One-Year Beta: 0.66 Founded in 1959, Packaging Corporation of America (NYSE: PKG) produces containerboard and corrugated packaging products as well as displays and package protection. Why Are We Out on PKG? Annual revenue growth of 1.4% over the last two years was below our standards for the industrials sector Gross margin of 22.7% is below its competitors, leaving less money to invest in areas like marketing and R&D Earnings per share have contracted by 4.2% annually over the last two years, a headwind for returns as stock prices often echo long-term EPS performance At $188.70 per share, Packaging Corporation of America trades at 11.5x forward EV-to-EBITDA. To fully understand why you should be careful with PKG, check out our full research report (it's free). Rolling One-Year Beta: 0.71 With over 2.5 million implants performed worldwide, STAAR Surgical (NASDAQ:STAA) designs and manufactures implantable lenses that correct vision problems without removing the eye's natural lens. Why Should You Sell STAA? Underwhelming constant currency revenue performance over the past two years suggests its product offering at current prices doesn't resonate with customers Free cash flow margin shrank by 26.6 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive Waning returns on capital imply its previous profit engines are losing steam STAAR Surgical's stock price of $16.20 implies a valuation ratio of 2.9x forward price-to-sales. Dive into our free research report to see why there are better opportunities than STAA. Rolling One-Year Beta: 0.59 Founded in 1894 as a response to the growing dangers of electricity in American homes and businesses, UL Solutions (NYSE:ULS) provides testing, inspection, and certification services that help companies ensure their products meet safety, security, and sustainability standards. Why Are We Hesitant About ULS? Annual revenue growth of 4.3% over the last three years was below our standards for the business services sector UL Solutions is trading at $70.40 per share, or 40.9x forward P/E. If you're considering ULS for your portfolio, see our FREE research report to learn more. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
Yahoo
22-05-2025
- Business
- Yahoo
STAAR Surgical Announces Participation in Upcoming Investor Conferences
LAKE FOREST, Calif., May 22, 2025--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2025 Virtual Ophthalmology ForumDate: Tuesday, May 27, 2025Format: Meetings and Webcast Fireside ChatWebcast: 2:00 PM ET, Webcast Link Wells Fargo 2025 West Coast Bus TourDate: Thursday, May 29, 2025Location: Laguna Beach, CAFormat: Fireside Chat; No Webcast William Blair 45th Annual Growth Stock ConferenceDate: Wednesday, June 4, 2025Location: Chicago, ILFormat: Meetings and Webcast Slide PresentationWebcast: 9:40 AM ET, Webcast Link Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Location: New York, NYFormat: Meetings Only Investor meeting participation is by invitation only from each sponsoring brokerage firm. The live and archived webcast for each event, where applicable, will also be available on STAAR's investor website at About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL's are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit To learn more about STAAR, visit We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the 'Investor Relations' sections at Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the Email Alerts section at View source version on Contacts Investors & Media Brian MooreVice President, Investor Relations and Corporate Development(626) 303-7902, Ext. 3023bmoore@ Investors - Asia Niko Liu, CFADirector, Investor Relations and Corporate Development - Asia+852-6092-5076nliu@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Business
- Business Wire
STAAR Surgical Announces Participation in Upcoming Investor Conferences
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Wells Fargo 2025 West Coast Bus Tou r Date: Thursday, May 29, 2025 Location: Laguna Beach, CA Format: Fireside Chat; No Webcast William Blair 45th Annual Growth Stock Conference Date: Wednesday, June 4, 2025 Location: Chicago, IL Format: Meetings and Webcast Slide Presentation Webcast: 9:40 AM ET, Webcast Link Jefferies Global Healthcare Conference Date: Thursday, June 5, 2025 Location: New York, NY Format: Meetings Only Investor meeting participation is by invitation only from each sponsoring brokerage firm. The live and archived webcast for each event, where applicable, will also be available on STAAR's investor website at About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL's are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit To learn more about STAAR, visit We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the 'Investor Relations' sections at Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the Email Alerts section at
Yahoo
16-05-2025
- Business
- Yahoo
STAAR Surgical plans $30m share buyback despite China market woes
Shares in STAAR Surgical jumped today (16 May) after the implantable lens developer revealed plans to bring $30m worth of shares back under ownership, a positive sign for the company despite revenue struggles due to weak demand in China. US-based STAAR, whose board authorised the share repurchase programme of outstanding common stock today, said the timing, manner, and price of any transactions will be determined at its discretion. STAAR had approximately 49.5 million shares of common stock outstanding as of March 2025. Shares in the Nasdaq-listed company rose 5% to a price of $19.25 at market open on 16 May following the announcement. STAAR has a market cap of $906m. STAAR may buy back share in the open market, through privately negotiated transactions, or by entering structured repurchase agreements with third parties. Block purchases, which involve buying a large number of shares to avoid market price fluctuations, could also be an avenue. STARR said that routes are alongside or under Rule 10b5-1 trading plans – a regulation that allows company insiders to trade stock without violating trading laws. STAAR stated it may modify or suspend the programme at any time, though it currently plans to continue it over the next six months. Buying back stock is a way for companies with auxiliary cash to boost earnings per share. It also increases the value of remaining shares and adjusts voting rights. However, the size and nature of buybacks depend on how much the company has in reserve. STAAR stated that the share repurchase will be funded from cash on hand and cash generated from operations. The company had $222.8m to call upon as of March 2025. Buying back shares has become a popular trend in 2025 as companies look to shore up ownership stakes amid an uncertain macroeconomic climate. In the pharmaceutical industry, Sanofi is executing a $5.1bn share buyback programme in 2025. 'Our decision to initiate a share repurchase programme underscores the boards and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth,' said STAAR Surgical's CEO Stephen C Farrell. STAAR struggled with revenue in 2024, posting just $49m in full-year results – a drop from $76.3m in 2023. During its 2024 earnings report, the company blamed the 'significant decline in China revenue' amid government initiatives affecting device procurement. It is an issue affecting a broad cohort of players in the medtech industry. Philips, for example, continues to expect a subdued demand for products in the region this year. STAAR's product line is called EVO, with various brands for myopia, astigmatism, and hyperopia. The devices are implantable collamer lenses (ICLs) that are administered during surgical procedures and offer long-term correction to vision. Although more expensive, ICLs – which are reversible – offer an alternative to laser-assisted approaches for those unsuitable for laser surgery or for those who do not want to have permanent changes to their eye. The global intraocular lens device market is forecast to grow to $5.6bn by 2034, up from $4.5bn in 2024, according to analysis by GlobalData. STAAR is estimated to occupy 1.8% of the global market share. "STAAR Surgical plans $30m share buyback despite China market woes" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
